WallStSmart
PM

Philip Morris International Inc

NYSE: PM · CONSUMER DEFENSIVE · TOBACCO

$184.30
+1.95% today

Updated 2026-06-12

Market cap
$270.66B
P/E ratio
24.46
P/S ratio
6.52x
EPS (TTM)
$7.10
Dividend yield
3.34%
52W range
$140 – $193
Volume
4.7M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Philip Morris International Inc (PM) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

PM · Philip Morris International Inc · Price target summary

Current
$184.30
Consensus
$192.56
+4.48%
2030 Target
$163.90
-11.07%
DCF
$109.96
-62.32% MoS
21 analysts:
10 Buy2 Hold0 Sell

Management guidance

Philip Morris held its 2026 Virtual Annual Meeting on May 6, 2026, with CEO Jacek Olczak highlighting strong 2025 performance with net revenues exceeding $40 billion and a robust start to 2026. The company raised its full-year 2026 EPS guidance (currency-adjusted) and emphasized continued growth from smoke-free products. Specific revenue targets for 2027-2030 were not disclosed in available guidance; however, management reiterated commitment to growth and shareholder returns amid transition to smoke-free portfolio.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

PM · Philip Morris International Inc · Revenue & price projection · 2023–2030E

Actual revenue Projected revenue Base case Bull to bear range
Bear case (2030)
$91.06
$58.1B Rev × 2.4x P/S
Base case (2030)
$163.90
$58.1B Rev × 4x P/S
Bull case (2030)
$254.95
$58.1B Rev × 6.4x P/S
WallStSmart.com

Financial forecast — research-backed

Metric20252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$40.6B$44.8B$47.6B$50.8B$54.3B$58.1B
Revenue growth7.3%10.2%6.3%6.7%6.9%6.9%
EPS$7.54$8.66$9.39$10.18$11.05$11.98
P/S ratio—4.0x4.0x4.0x4.0x4.0x
Implied price—$127.48$127.48$145.69$145.69$163.90

PM · Philip Morris International Inc · Catalysts & risks

Growth catalysts
+ FDA reauthorization of IQOS as Modified Risk Tobacco Product (April 2026) reducing regulatory uncertainty
+ New FDA guidance on nicotine pouches easing enforcement threats for ZYN products, enabling ZYN Ultra launch
+ Smoke-free product penetration reaching 43% of net revenue with IQOS and oral nicotine pouches driving mid-to-high single digit growth
+ Strategic partnerships expansion (Ducati Corse, Ferrari Hypersail) enhancing brand positioning in premium segments
+ Continued geographic expansion and pricing power in international markets offsetting combustible volume declines
Key risks
- Regulatory headwinds: Potential FDA restrictions on nicotine products, flavored vape bans, or IQOS modified risk claims reversal
- Combustible cigarette volume declines accelerating faster than smoke-free growth can offset; illicit trade at 33% in Americas
- Nicotine pouch market competition intensifying from Altria (on! PLUS) and other entrants; ZYN launch delays creating revenue timing risk
- FX headwinds given 75%+ international revenue exposure; geopolitical tensions impacting emerging markets
- High leverage (EV/EBITDA 21.3x) and debt servicing costs limiting capital flexibility if growth decelerates

Methodology

Philip Morris International Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 15, 2026.